首页> 外文学位 >To improve solubility and stability of poorly water-soluble drug by using colloidal silicon dioxide as surface adsorbent in solid dispersion technique
【24h】

To improve solubility and stability of poorly water-soluble drug by using colloidal silicon dioxide as surface adsorbent in solid dispersion technique

机译:固体分散技术中以胶体二氧化硅为表面吸附剂,提高水溶性差的药物的溶解性和稳定性

获取原文
获取原文并翻译 | 示例

摘要

Most of new drug entities developed have less aqueous solubility. They belong to BCS class II as they have less aqueous solubility and high permeability. For oral dosage forms bioavailability and dissolution plays important role. Poor solubility of drug affect bioavailability and dissolution of drug. Therefore, enhancing solubility of poor water-soluble drug is a challenge. There various techniques to improve solubility of drug. Solid dispersion is one of the technique to enhance solubility and dissolution rate of less soluble drugs. It is efficient and widely used technique.;Crystalline form of drug has less aqueous solubility as compare to amorphous form. Solid dispersion technique involves conversion of crystalline form of drug to amorphous therefore enhancing solubility of drug. Solid dispersion consists of 2 components, hydrophilic polymer and hydrophobic drug.;The drug in amorphous state in solid dispersion is thermodynamically less stable. The amorphous molecules have high molecular mobility and high energy. Therefore, they have high tendency to recrystallize the drug affecting solubility and dissolution of drug. Different stabilizers, porous materials or absorbents can be used to enhance stability of amorphous solid dispersion. Colloidal silicon dioxide can be used as stabilizer. Colloidal silica has high surface area and pore volume. Therefore, reduces the mobility of drug molecule and stabilize amorphous solid dispersion by preventing recrystallization of drug.;In this study fenofibrate was selected as model drug to study the enhancement in solubility and stability in solid dispersion. It is BCS Class II drug. Fenofibrate was selected as it has high tendency to crystallize and it also has very less water solubility. HPMC was selected as polymeric component of solid dispersion. HPMC is available in different grades. For this study HPMC E5 (METHOCEL LV E5) was used. Two different grades of colloidal silica were used. SYLOID 244FP and AEROSIL 200 are different grades of colloidal silica.;There are various techniques to form solid dispersion. In this study, solid dispersion was formed by using spray drying technology. BUCHI mini spray dryer B290 was used. It is solvent evaporation technique to form solid dispersion. Spray drying is a complex process and several parameters need to be adjusted. Some of the parameters like inlet air temperature, solvent; flow rate, nozzle size, drying gas air flow were kept constant to avoid variation in the experiments. Optimum ratio of drug and polymer to form solid dispersion was determined.;All solid dispersions were made keeping the ratio of drug and polymer same and both stabilizers were used in different ratio in different dispersion. All solid dispersions were further characterized by MDSC, X-ray Diffraction Pattern, FTIR. Enhancement of solubility was determined by Dissolution. Dissolution tests were carried out in sink and non-sink conditions. All solid dispersions were also subjected to accelerated stability conditions to check the stability of drug in solid dispersion.;The results form dissolution was compared to dissolution of pure drug as well as with physical mixture of drug, polymer and stabilizer and also with external solid dispersion. The MDSC, x-ray diffraction, FTIR results of stability samples after 2 weeks, 4 weeks and 6 weeks were with initial samples.;Overall it can be summarized that use of stabilizers help to improve stability as well as stability of solid dispersion. Increasing concentration of stabilizer increases rate of dissolution. Solid dispersion showed higher dissolution as compared to pure drug and physical mixtures. However, solid dispersion containing aerosil were more stable as compared to one with syloid.
机译:开发的大多数新药物实体的水溶性较小。它们属于BCS II类,因为它们具有较少的水溶性和高渗透性。对于口服剂型,生物利用度和溶解度起着重要作用。药物溶解度差会影响药物的生物利用度和溶解度。因此,提高不良水溶性药物的溶解度是一个挑战。有多种提高药物溶解度的技术。固体分散体是提高难溶性药物的溶解度和溶解速度的技术之一。它是一种有效且广泛使用的技术。结晶形式的药物与无定形形式相比,水溶性较低。固体分散技术涉及药物的结晶形式向无定形的转化,因此提高了药物的溶解度。固体分散体由亲水聚合物和疏水性药物两部分组成。固体分散体中的非晶态药物在热力学上不稳定。无定形分子具有高的分子迁移率和高的能量。因此,它们具有使药物重结晶的高趋势,从而影响药物的溶解性和溶解性。可以使用不同的稳定剂,多孔材料或吸收剂来增强无定形固体分散体的稳定性。胶态二氧化硅可用作稳定剂。胶态二氧化硅具有高的表面积和孔体积。因此,通过防止药物的重结晶来降低药物分子的迁移率并稳定无定形固体分散体。;在本研究中,选择非诺贝特作为模型药物,以研究固体分散体中溶解度和稳定性的提高。它是BCS II类药物。选择非诺贝特是因为它具有很高的结晶倾向,并且其水溶性也非常低。选择HPMC作为固体分散体的聚合物组分。 HPMC有不同等级。在这项研究中,使用了HPMC E5(METHOCEL LV E5)。使用了两种不同等级的胶体二氧化硅。 SYLOID 244FP和AEROSIL 200是不同等级的胶体二氧化硅。;有多种技术可形成固体分散体。在这项研究中,固体分散体是通过使用喷雾干燥技术形成的。使用了BUCHI迷你喷雾干燥器B290。是溶剂蒸发技术,形成固体分散体。喷雾干燥是一个复杂的过程,需要调整几个参数。一些参数如进气温度,溶剂;流速,喷嘴尺寸,干燥气体气流应保持恒定以避免实验变化。确定了药物和聚合物形成固体分散体的最佳比例。所有制备的固体分散体均保持药物和聚合物的比例相同,两种稳定剂在不同分散体中的使用比例不同。通过MDSC,X射线衍射图,FTIR进一步表征所有固体分散体。通过溶解确定溶解度的提高。在水槽和非水槽条件下进行溶解测试。所有固体分散体也要经受加速的稳定性条件,以检查药物在固体分散体中的稳定性。将溶出的结果与纯药物以及药物,聚合物和稳定剂的物理混合物以及外部固体分散体的溶出进行比较。 2周,4周和6周后的稳定性样品的MDSC,x射线衍射,FTIR结果与初始样品相同。总体上可以总结出,使用稳定剂有助于提高固体分散体的稳定性和稳定性。稳定剂浓度的增加会增加溶解速度。与纯药物和物理混合物相比,固体分散体显示出更高的溶解度。但是,与使用胶体的固体分散体相比,含Aerosil的固体分散体更稳定。

著录项

  • 作者

    Bhadiyadra, Mittal.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Pharmaceutical sciences.
  • 学位 M.S.
  • 年度 2018
  • 页码 113 p.
  • 总页数 113
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号